Therapeutic Effects of 30 nm Cyclosporin A-Loaded Nanoparticles Using PLGA-PEG-PLGA Triblock Copolymer for Transdermal Delivery in Mouse Models of …
A Kagawa, A Sato, K Makino, I Takeuchi - Applied Sciences, 2024 - mdpi.com
This study aimed to evaluate the effectiveness of poly (DL-lactide-co-glycolide)-block-poly
(ethylene glycol)-block-poly (dl-lactide-co-glycolide) triblock copolymers (PLGA-PEG-PLGA) …
(ethylene glycol)-block-poly (dl-lactide-co-glycolide) triblock copolymers (PLGA-PEG-PLGA) …
Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea
BS Kim, DH Kim, BS Shin, ES Lee… - … in Chronic Disease, 2024 - journals.sagepub.com
Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for
the treatment of moderate to severe psoriasis in September 2015. Objectives: To assess the …
the treatment of moderate to severe psoriasis in September 2015. Objectives: To assess the …
Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
X Lu, W Wang - Clinical, Cosmetic and Investigational …, 2023 - Taylor & Francis
Erythrodermic psoriasis (EP) is a rare and severe type of psoriasis. Common systemic
therapies for children with EP include treatment with glucocorticoids, cyclosporine, acitretin …
therapies for children with EP include treatment with glucocorticoids, cyclosporine, acitretin …
Secukinumab-Induced Bullous Pemphigoid in a Patient With Psoriatic Arthritis
To the Editor: We present the case of a 62-year-old man with a history of skin psoriasis and
psoriatic arthritis (PsA) who had previously failed adalimumab and apremilast. He was …
psoriatic arthritis (PsA) who had previously failed adalimumab and apremilast. He was …
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
R Ramonda, M Lorenzin, MS Chimenti, F Atzeni… - 2024 - researchsquare.com
Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and
safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA …
safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA …